Core Insights - OKYO Pharma Limited has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, enhancing its ability to access capital markets efficiently [1][2] - The new partnership with Leerink Partners is expected to provide financial flexibility to support ongoing clinical development, particularly for its lead candidate urcosimod for neuropathic corneal pain [2] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares listed on the Nasdaq Capital Market [4] - The company recently completed a successful Phase 2 trial of urcosimod and plans to initiate a Phase 2b/3 multiple-dose study involving approximately 150 subjects in the first half of the year [4]

Core Insights - OKYO Pharma Limited has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, enhancing its ability to access capital markets efficiently [1][2] - The new partnership with Leerink Partners is expected to provide financial flexibility to support ongoing clinical development, particularly for its lead candidate urcosimod for neuropathic corneal pain [2] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares listed on the Nasdaq Capital Market [4] - The company recently completed a successful Phase 2 trial of urcosimod and plans to initiate a Phase 2b/3 multiple-dose study involving approximately 150 subjects in the first half of the year [4]

Core Insights - Royalty Pharma experienced a "landmark year" in 2025, achieving double-digit growth in both portfolio and royalty receipts, and internalizing its external manager to enhance governance and reduce costs [2][5][18] Financial Performance - The company reported a return on invested capital (ROIC) of 15.8% and return on equity (ROE) of 22.8% for 2025 [5] - Royalty receipts grew by 13% for the year and 17% in the fourth quarter, while portfolio receipts increased by 16% for the year and 18% in the fourth quarter [13] - The company ended 2025 with $619 million in cash, $9.2 billion in debt, and a leverage ratio of approximately 3x [3][15] Cost Management - Management expects to achieve $100 million in cost savings in 2026 due to the internalization of the external manager, aiming for an operating and professional cost ratio of 4%–5% over time [1][5] Strategic Transactions - In 2025, Royalty Pharma executed eight transactions with a total announced value of $4.7 billion, deploying $2.6 billion, marking its strongest year for synthetic royalties [4][6][7] - The company reviewed over 480 potential royalty transactions, resulting in 109 in-depth reviews and 35 proposals [6] 2026 Guidance - For 2026, management guided portfolio receipts of $3.275 billion to $3.425 billion, implying a royalty growth of approximately 3% to 8% [3][16] - The guidance reflects anticipated headwinds from product loss of exclusivity and the introduction of biosimilars [2][16] Pipeline and Future Catalysts - The company estimates combined peak sales of over $43 billion across 20 development-stage therapies, translating to more than $2.1 billion in peak annual royalties [11] - Upcoming pivotal readouts are expected over the next 24 months, including data from Revolution Medicines and Novartis [17] Capital Allocation - Royalty Pharma returned $1.7 billion to shareholders in 2025 through $1.2 billion in buybacks and over $500 million in dividends [14]

Core Viewpoint - Biofrontera Inc. has received FDA acceptance for its supplemental New Drug Application for Ameluz, which could expand its use to treat superficial basal cell carcinoma (sBCC) if approved, addressing a significant unmet medical need in dermatology [1][4][6]. Group 1: FDA Approval and Market Potential - The FDA has completed its review and accepted the filing of Biofrontera's sNDA for Ameluz, with a PDUFA target action date set for September 28, 2026 [1][6]. - If approved, this indication would significantly expand the Ameluz PDT platform beyond its current use for actinic keratosis, validating Biofrontera's photodynamic therapy approach [2][4]. - The potential approval would make Ameluz the first PDT photosensitizer indicated for the treatment of sBCC in the U.S., which is the most common skin cancer with approximately 3.6 million cases diagnosed annually [6][8]. Group 2: Clinical Significance and Treatment Options - Basal cell carcinoma (BCC) is prevalent in the U.S., with estimates suggesting that 10-25% of cases are of the superficial subtype, highlighting the need for effective treatment options [3][6]. - Current treatment methods often involve surgical or destructive approaches, which may not be suitable for all patients, indicating a demand for non-invasive alternatives like Ameluz PDT [3][4]. Group 3: Company Strategy and Leadership - The CEO of Biofrontera emphasized the importance of this milestone in expanding the clinical utility of Ameluz and reinforcing photodynamic therapy as a versatile platform in dermatology [4]. - The company believes that the new indication for Ameluz has the potential to significantly expand its addressable market and strengthen its position in medical dermatology [4].

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS"). The claim, originally made on January 14, 2026, and amplified on January 26, 2026, alleged, among other things, improper and oppressive actions on the part of the Company against KAOS, resulting in KAOS suffering alleged damages (the "KAOS Allegations"). Th ...

Financial Data and Key Metrics Changes - Royalty Pharma achieved strong double-digit growth in both portfolio receipts and royalty receipts, with portfolio receipts growing 18% in Q4 and 16% for the full year [25][5] - Return on invested capital was 15.8% and return on invested equity was 22.8% for the year, reflecting strong returns [28][5] - The company raised its guidance three times during the year, delivering results slightly above the top end of the most recent update [5][6] Business Line Data and Key Metrics Changes - The company deployed $2.6 billion in capital for the year, with 67% of investments in approved products and 33% in development stage therapies [18][31] - Synthetic royalty transactions reached a record value of $4.7 billion in 2025, exceeding traditional royalties for the first time [15][61] - Royalty receipts from key products like Voranigo, Trelstar, and Tremfya contributed significantly to growth, with minimal contribution from new acquisitions [27][25] Market Data and Key Metrics Changes - The biopharma market reached $10 billion in announced transaction value for the first time, with a strong growth trajectory observed [9] - The average annual transaction value in the biopharma market nearly doubled over the past five years compared to the previous five years [9] Company Strategy and Development Direction - Royalty Pharma aims to be the premier capital allocator in life sciences, focusing on consistent compounding growth and shareholder value creation [5][6] - The company is excited about expanding its team and platform in China, indicating a strategic focus on international growth [36][73] - The internalization of the external manager is expected to enhance governance and reduce costs, aligning intellectual capital with the royalty portfolio [7][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business, highlighting the potential for significant value creation from the development stage pipeline [11][12] - The company anticipates continued growth driven by the increasing recognition of biopharma royalties and the demand for capital in life sciences [10][11] - Future guidance for 2026 indicates expected growth in royalty receipts of 3%-8%, despite anticipated losses from exclusivity expirations [32][35] Other Important Information - The company returned $1.7 billion to shareholders through share repurchases and dividends, with a 7% increase in dividends announced for Q1 2026 [8][31] - The company expects to maintain a high level of cash conversion and efficiency, with operating costs projected to decrease significantly in 2026 [33][25] Q&A Session Summary Question: Sustainability of dividends and buybacks - Management indicated that capital allocation will be based on the relative attractiveness of royalty opportunities versus stock price value, with a current bias towards royalties [40][42] Question: Involvement in private companies and capital markets - Management is open to exploring high-quality assets in private companies and remains focused on investing in high-quality pharmaceutical products [44][42] Question: Performance of Alyftrek and patient conversion - Management noted that the conversion to Alyftrek has been gradual but consistent, with expectations for continued contributions from the cystic fibrosis franchise [48][52] Question: General medicine and cardiometabolic disease categories - Management expressed excitement about opportunities in the cardiovascular space, emphasizing a diverse approach to drug delivery formats [59][54] Question: Synthetic royalties trend - Management is optimistic about the growth of synthetic royalties, noting increased awareness and demand for this funding model [61][62] Question: Lp(a) class of drugs and trial outcomes - Management remains enthusiastic about the Lp(a) class, with no change in outlook despite trial delays, awaiting results from Novartis [63][64] Question: Underappreciated assets in the portfolio - Management highlighted significant potential in the pipeline, with several products expected to deliver substantial value [70][69] Question: China opportunity and strategic focus - Management is excited about the growing opportunity in China, with plans to expand the team and platform in the region [73][72]

Financial Data and Key Metrics Changes - Royalty Pharma achieved strong double-digit growth in both portfolio receipts and royalty receipts, with portfolio receipts growing 16% for the year and royalty receipts growing 13% [5][24] - The company maintained a return on invested capital of 15.8% and a return on invested equity of 22.8% for the year [5][27] - The company returned $1.7 billion to shareholders, including $1.2 billion in share repurchases and over $500 million in dividends, with a 7% increase in dividends announced for the first quarter of 2026 [7][29] Business Line Data and Key Metrics Changes - The company reported strong performance from key products such as Voranigo, Trelstar, TREMFYA, and the cystic fibrosis franchise, contributing to the growth in royalty receipts [26] - In 2025, synthetic royalty transactions reached a record value of $4.7 billion, significantly higher than previous years, indicating a growing trend in this funding modality [14][15] Market Data and Key Metrics Changes - The biopharma market reached $10 billion in announced transaction value for the first time in 2025, with a strong growth trajectory observed over the past five years [8] - The company noted that the demand for capital in life sciences is increasing, driven by the recognition of the benefits of biopharma royalties [9] Company Strategy and Development Direction - Royalty Pharma aims to be the premier capital allocator in life sciences, focusing on consistent compounding growth and shareholder value creation [5][10] - The company plans to continue expanding its capital deployment strategy, with a focus on high-quality assets and innovative therapies [12][16] - The internalization of the external manager is expected to enhance governance and reduce costs, further supporting the company's strategic goals [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to deliver consistent returns, even in uncertain market conditions [10][11] - The guidance for 2026 indicates expected growth in royalty receipts of 3%-8%, reflecting the strength of the existing portfolio [30][33] - Management highlighted the potential for significant value creation from the development stage pipeline, with multiple pivotal readouts expected in the near term [20][22] Other Important Information - The company achieved its five-year capital deployment target of $10 billion-$12 billion one year ahead of schedule [10][17] - The company has a robust pipeline of 20 development-stage therapies, with estimated combined peak sales of over $43 billion, translating to over $2.1 billion in peak annual royalties [22] Q&A Session Summary Question: Sustainability of dividends and buybacks in 2026 - Management indicated that capital allocation will be based on the relative attractiveness of royalty opportunities versus stock price value, with a focus on returning capital to shareholders while prioritizing royalty investments [38][40] Question: Involvement in private companies and capital markets - Management stated that they are open to investing in high-quality assets within private companies and are excited about the growth of opportunities in the sector [42] Question: Performance of ALYFTREK and patient conversion - Management noted that the conversion to ALYFTREK has been gradual but consistent, with expectations for continued contributions from the cystic fibrosis franchise [45][50] Question: General medicine and cardiometabolic disease categories - Management expressed excitement about opportunities in the cardiovascular and cardiometabolic markets, emphasizing a diversified approach to drug delivery formats [51][52] Question: Future of synthetic royalties - Management is optimistic about the continued growth of synthetic royalties, highlighting their advantages over traditional financing methods [56][59] Question: Lp(a) class of drugs and trial outcomes - Management remains enthusiastic about the Lp(a) class and is awaiting results from ongoing trials, with no change in their positive outlook [60][61] Question: Underappreciated assets in the portfolio - Management highlighted the significant potential for value creation in the pipeline, with several products expected to deliver strong returns [66][68] Question: China opportunity and strategic focus - Management is excited about the growing opportunity in China and is looking to expand their team and platform in the region [69][71] Question: Teva's IL-15 asset and mid-stage investments - Management explained that the investment in Teva's asset was driven by the unmet need in the vitiligo market and emphasized their flexible investment structure [76][78] Question: Growth potential of VORANIGO - Management expressed strong confidence in the growth trajectory of VORANIGO, anticipating it to become a blockbuster product [79][80]

Core Viewpoint - Outlook Therapeutics has submitted a Type A meeting request to the FDA following a Complete Response Letter regarding its Biologics License Application for ONS-5010/LYTENAVA™ for wet AMD treatment, citing a deficiency in evidence of effectiveness [1][2] Group 1: Regulatory Developments - The Complete Response Letter identified a single deficiency related to the lack of substantial evidence of effectiveness and recommended additional confirmatory evidence [2] - Outlook Therapeutics believes the FDA's determination is inconsistent with the totality of evidence submitted, including data from a well-controlled study [2] - The company conducted informal meetings with the FDA prior to submitting the Type A meeting request to discuss the CRL [2] Group 2: Clinical Evidence - ONS-5010 is supported by data from the NORSE TWO Phase 3 trial, which showed statistically significant improvements in visual acuity at 12 months, meeting its primary endpoint [3] - NORSE EIGHT, another Phase 3 study, provided additional evidence of efficacy despite not meeting its primary endpoint at 8 weeks, showing consistent gains in visual acuity [4] - A comprehensive package of confirmatory evidence was submitted, including mechanistic and pharmacodynamic data demonstrating VEGF inhibition [5] Group 3: Safety and Manufacturing - ONS-5010 demonstrated a favorable safety profile, with ocular adverse reactions consistent with the control arm and no safety concerns raised by the FDA [6] - The product is supported by a fully domestic U.S. manufacturing supply chain, enhancing reliability and aligning with public health objectives [7] Group 4: Market Authorization - LYTENAVA™ has received Marketing Authorization in the EU and UK for wet AMD treatment and became commercially available in Germany and the UK in June 2025 [8] - It is the first authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK [9] - Outlook Therapeutics is exploring collaborations for commercial and distribution partnerships in additional European countries and beyond [8]

Core Insights - Spero Therapeutics, Inc. is focused on developing tebipenem HBr, an investigational oral carbapenem aimed at treating complicated urinary tract infections (cUTI), including pyelonephritis [1] Group 1: Clinical Development - The Phase 3 trial (PIVOT-PO) for tebipenem HBr has successfully met its primary endpoint and was stopped early due to positive results [1]

SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: Regulatory and Development Strategy - Clarity ...